{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T17:27:26Z","timestamp":1767374846170,"version":"build-2065373602"},"reference-count":117,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04138\/2020","UIDP\/04138\/2020"],"award-info":[{"award-number":["UIDB\/04138\/2020","UIDP\/04138\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.autrev.2020.102730","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:43:34Z","timestamp":1608165814000},"page":"102730","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Targeted delivery in scleroderma fibrosis"],"prefix":"10.1016","volume":"20","author":[{"given":"Carla","family":"Varrica","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena Sofia","family":"Dias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catarina","family":"Reis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Carvalheiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Sim\u00f5es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2020.102730_bb0005","series-title":"Targeted therapy for scleroderma fibrosis challenges in scleroderma treatment","first-page":"1","volume":"6","author":"Schoenfeld","year":"2016"},{"key":"10.1016\/j.autrev.2020.102730_bb0010","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.autrev.2010.09.015","article-title":"Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy","volume":"10","author":"Wei","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102730_bb0015","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5301\/jsrd.5000249","article-title":"Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities","volume":"2","author":"Varga","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.autrev.2020.102730_bb0020","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/1756-185X.13764","article-title":"Adipose-derived stromal\/stem cells successfully attenuate the fibrosis of scleroderma mouse models","volume":"23","author":"Okamura","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102730_bb0025","doi-asserted-by":"crossref","first-page":"102583","DOI":"10.1016\/j.autrev.2020.102583","article-title":"Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets","volume":"19","author":"Mahler","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102730_bb0030","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/art.22698","article-title":"Impairment of endothelial cell differentiation from bone marrow\u2013derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis","volume":"56","author":"Cipriani","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102730_bb0035","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.jid.2017.01.011","article-title":"Bone marrow-derived mesenchymal stem cells expressing Thioredoxin 1 attenuate bleomycin-induced skin fibrosis and oxidative stress in scleroderma","volume":"137","author":"Jiang","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2020.102730_bb0040","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.clindermatol.2013.01.010","article-title":"Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies","volume":"31","author":"Fett","year":"2013","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.autrev.2020.102730_bb0045","first-page":"1801","article-title":"Statins: potentially useful in therapy of systemic sclerosis-related Raynaud\u2019s phenomenon and digital ulcers","volume":"35","author":"Abou-Raya","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2020.102730_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/4569826","article-title":"Systemic sclerosis pathogenesis and emerging therapies, beyond the fibroblast","volume":"2019","author":"Sierra-Sep\u00falveda","year":"2019","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.autrev.2020.102730_bb0055","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102730_bb0060","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00281-015-0551-z","article-title":"Systemic sclerosis and localized scleroderma\u2014current concepts and novel targets for therapy","volume":"38","author":"Distler","year":"2015","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.autrev.2020.102730_bb0065","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/art.40560","article-title":"Treatment algorithms for systemic sclerosis according to experts","volume":"70","author":"Fern\u00e1ndez-Codina","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2020.102730_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102494","article-title":"Gender-related differences in systemic sclerosis","volume":"19","author":"Hughes","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102730_bb0075","doi-asserted-by":"crossref","first-page":"102507","DOI":"10.1016\/j.autrev.2020.102507","article-title":"Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: derivation and internal validation","volume":"19","author":"Rubio-Rivas","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102730_bb0080","doi-asserted-by":"crossref","first-page":"102515","DOI":"10.1016\/j.autrev.2020.102515","article-title":"Diagnostic profiles for precision medicine in systemic sclerosis; stepping forward from single biomarkers towards pathophysiological panels","volume":"19","author":"Smeets","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102730_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02383","article-title":"Ubiquitination in scleroderma fibrosis and its treatment","volume":"9","author":"Long","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2020.102730_bb0090","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.autrev.2020.102730_bb0095","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrrheum.2017.190","article-title":"STAT3 \u2014 a key integrator of profibrotic signalling","volume":"13","author":"Mchugh","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2020.102730_bb0100","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/nrrheum.2009.26","article-title":"Transforming growth factor \u03b2 as a therapeutic target in systemic sclerosis","volume":"5","author":"Varga","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2020.102730_bb0105","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/art.27220","article-title":"A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis","volume":"62","author":"Farina","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102730_bb0110","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41584-019-0184-z","article-title":"Emerging targets of disease-modifying therapy for systemic sclerosis","volume":"15","author":"Volkmann","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2020.102730_bb0115","doi-asserted-by":"crossref","first-page":"102396","DOI":"10.1016\/j.autrev.2019.102396","article-title":"Role of microRNA in the pathogenesis of systemic sclerosis tissue fibrosis and vasculopathy","volume":"18","author":"Henry","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102730_bb0120","first-page":"1","article-title":"Systemic sclerosis: new insights in autoimmunity","volume":"222","author":"Kaal","year":"1999","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.autrev.2020.102730_bb0125","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/art.20160","article-title":"A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease","volume":"50","author":"Ruzek","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102730_bb0130","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/2211-5463.12268","article-title":"A modified graft-versus-host-induced model for systemic sclerosis, with pulmonary fibrosis in Rag2-deficient mice","volume":"7","author":"Yang","year":"2017","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.autrev.2020.102730_bb0135","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1164\/ajrccm.159.1.9802104","article-title":"Lovastatin induces fibroblast apoptosisin vitroandin vivo","volume":"159","author":"Tan","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2020.102730_bb0140","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1002\/art.27647","article-title":"Animal models of systemic sclerosis: prospects and limitations","volume":"62","author":"Beyer","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102730_bb0145","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-014-0425-8","article-title":"Personalized medicine in systemic sclerosis: facts and promises","volume":"16","author":"Dobrota","year":"2014","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2020.102730_bb0150","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1527-3466.2006.00077.x","article-title":"Oxidative stress as the leading cause of acute myocardial infarction in diabetics","volume":"24","author":"Di Filippo","year":"2006","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1016\/j.autrev.2020.102730_bb0155","doi-asserted-by":"crossref","first-page":"102403","DOI":"10.1016\/j.autrev.2019.102403","article-title":"Is there today a place for corticosteroids in the treatment of scleroderma?","volume":"18","author":"Blagojevic","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102730_bb0160","doi-asserted-by":"crossref","first-page":"102431","DOI":"10.1016\/j.autrev.2019.102431","article-title":"Corticosteroid-sparing benefit of intravenous immunoglobulin in systemic sclerosis-associated myopathy: a comparative study in 52 patients","volume":"19","author":"Chaigne","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"1377\u20131386","key":"10.1016\/j.autrev.2020.102730_bb0165","article-title":"Simvastatin attenuates the development of pulmonary and cutaneous fibrosis in a murine model of systemic sclerosis","volume":"52","author":"Bagnato","year":"2013","journal-title":"Rheumatol (UK)"},{"key":"10.1016\/j.autrev.2020.102730_bb0170","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0889-857X(05)70296-9","article-title":"Immunopathogenesis of systemic sclerosis","volume":"22","author":"White","year":"1996","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.autrev.2020.102730_bb0175","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/art.23146","article-title":"Heparan sulfate\u2013dependent ERK activation contributes to the overexpression of fibrotic proteins and enhanced contraction by scleroderma fibroblasts","volume":"58","author":"Chen","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102730_bb0180","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1096\/fj.07-105627","article-title":"Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis","volume":"22","author":"Akhmetshina","year":"2008","journal-title":"FASEB J"},{"key":"10.1016\/j.autrev.2020.102730_bb0185","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.ajpath.2012.07.017","article-title":"Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease","volume":"181","author":"Zerr","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2020.102730_bb0190","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1172\/JCI200419603","article-title":"Imatinib mesylate inhibits the profibrogenic activity of TGF-\u03b2 and prevents bleomycin-mediated lung fibrosis","volume":"114","author":"Daniels","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2020.102730_bb0195","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2010.13050","article-title":"Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?","author":"Beyer","year":"2010","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.autrev.2020.102730_bb0200","doi-asserted-by":"crossref","first-page":"102467","DOI":"10.1016\/j.autrev.2020.102467","article-title":"Combination vasodilator therapy improves skin microvascular blood but do not restore endothelial function in systemic sclerosis","volume":"19","author":"Hariri","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102730_bb0205","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/BOR.0b013e328337c3d6","article-title":"Innovative therapies for systemic sclerosis","volume":"22","author":"Ong","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2020.102730_bb0210","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/art.21526","article-title":"Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes","volume":"54","author":"Matsushita","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102730_bb0215","doi-asserted-by":"crossref","first-page":"R168","DOI":"10.1186\/ar4352","article-title":"B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis","volume":"15","author":"Fran\u00e7ois","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2020.102730_bb0220","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aas9944","article-title":"BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance","volume":"4","author":"Matsushita","year":"2018","journal-title":"Sci Adv"},{"key":"10.1016\/j.autrev.2020.102730_bb0225","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/ni0901-764","article-title":"Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity","volume":"2","author":"Lipsky","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2020.102730_bb0230","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/art.20274","article-title":"Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells","volume":"50","author":"Sato","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102730_bb0235","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/rheumatology\/kev331","article-title":"Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity","volume":"55","author":"Matsushita","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2020.102730_bb0240","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1084\/jem.20111675","article-title":"B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6\u2013producing B cells","volume":"209","author":"Barr","year":"2012","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2020.102730_bb0245","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11498","article-title":"Marginal zone B cells exacerbate endotoxic shock via interleukin-6 secretion induced by Fc\u03b1\/\u03bcR-coupled TLR4 signalling","volume":"7","author":"Honda","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2020.102730_bb0250","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/nature11501","article-title":"Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions","volume":"491","author":"Yoshizaki","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2020.102730_bb0255","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.immuni.2008.03.017","article-title":"A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses","volume":"28","author":"Yanaba","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2020.102730_bb0260","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jaci.2015.12.1319","article-title":"A novel splenic B1 regulatory cell subset suppresses allergic disease through phosphatidylinositol 3-kinase\u2013Akt pathway activation","volume":"138","author":"Matsushita","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2020.102730_bb0265","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1126\/science.285.5425.260","article-title":"BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator","volume":"285","author":"Moore","year":"1999","journal-title":"Science (80- )"},{"key":"10.1016\/j.autrev.2020.102730_bb0270","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1038\/sj.jid.5700919","article-title":"BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice","volume":"127","author":"Matsushita","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2020.102730_bb0275","doi-asserted-by":"crossref","DOI":"10.1172\/JCI36030","article-title":"Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression","author":"Matsushita","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2020.102730_bb0280","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.4049\/jimmunol.0902391","article-title":"Protective and pathogenic roles for B cells during systemic autoimmunity in NZB\/W F1 mice","volume":"184","author":"Haas","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2020.102730_bb0285","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102730_bb0290","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102730_bb0295","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrrheum.2011.149","article-title":"Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities","volume":"8","author":"Bhattacharyya","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2020.102730_bb0300","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrrheum.2009.82","article-title":"Tyrosine kinases as targets for the treatment of rheumatoid arthritis","volume":"5","author":"D\u2019aura Swanson","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2020.102730_bb0305","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jid.2018.08.021","article-title":"Notch signaling activity determines uptake and biological effect of Imatinib in systemic sclerosis dermal fibroblasts","volume":"139","author":"Harrach","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2020.102730_bb0310","doi-asserted-by":"crossref","first-page":"i48","DOI":"10.1136\/ard.2009.120196","article-title":"Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies","volume":"69","author":"Distler","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102730_bb0315","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1172\/JCI116235","article-title":"Coexpression of phosphotyrosine-containing proteins, platelet-derived growth factor-B, and fibroblast growth factor-1 in situ in synovial tissues of patients with rheumatoid arthritis and Lewis rats with adjuvant or streptococcal cell wall arthritis","volume":"91","author":"Sano","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2020.102730_bb0320","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/art.22314","article-title":"Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis","volume":"56","author":"Distler","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102730_bb0325","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/art.24186","article-title":"Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis","volume":"60","author":"Akhmetshina","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102730_bb0330","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/BOR.0b013e3283454124","article-title":"New therapies in the management of rheumatoid arthritis","volume":"23","author":"Buch","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2020.102730_bb0335","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-12-43","article-title":"What is the future of targeted therapy in rheumatology: biologics or small molecules?","volume":"12","author":"M\u00f3csai","year":"2014","journal-title":"BMC Med"},{"key":"10.1016\/j.autrev.2020.102730_bb0340","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/17425255.2011.547474","article-title":"Role of organic cation transporters in drug-induced toxicity","volume":"7","author":"Ciarimboli","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.autrev.2020.102730_bb0345","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1\u2013mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2020.102730_bb0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052247","article-title":"Transport mechanisms and their pathology-induced regulation govern tyrosine kinase inhibitor delivery in rheumatoid arthritis","volume":"7","author":"Schmidt-Lauber","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2020.102730_bb0355","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.79","article-title":"MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients","volume":"6","author":"Harrach","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.autrev.2020.102730_bb0360","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.1002\/jcph.706","article-title":"The role of transporters in the toxicity of chemotherapeutic drugs: focus on transporters for organic cations","volume":"56","author":"Hucke","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.autrev.2020.102730_bb0365","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.3816\/CLM.2007.s.010","article-title":"Emerging safety issues with Imatinib and other Abl tyrosine kinase inhibitors","volume":"7","author":"Atallah","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.autrev.2020.102730_bb0370","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0084-3873(08)79180-6","article-title":"Follow-up of patients receiving imatinib for chronic myeloid Leukemia","volume":"2008","author":"Loehrer","year":"2008","journal-title":"Yearb Med"},{"issue":"220","key":"10.1016\/j.autrev.2020.102730_bb0375","article-title":"Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis","volume":"11","author":"Beyer","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2020.102730_bb0380","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2018-213031","article-title":"Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis","volume":"77","author":"Denton","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102730_bb0385","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1093\/rheumatology\/keq275","article-title":"The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab","volume":"49","author":"Shima","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2020.102730_bb0390","doi-asserted-by":"crossref","first-page":"R157","DOI":"10.1186\/ar4672","article-title":"Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis","volume":"16","author":"Desallais","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2020.102730_bb0395","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0923-1811(01)00128-1","article-title":"Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis","volume":"27","author":"Sato","year":"2001","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.autrev.2020.102730_bb0400","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3899\/jrheum.120725","article-title":"Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis","volume":"40","author":"De Lauretis","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2020.102730_bb0405","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1136\/annrheumdis-2011-200955","article-title":"Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis","volume":"71","author":"Khan","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102730_bb0410","article-title":"Interleukin-6: a new therapeutic target in systemic sclerosis?","volume":"2","author":"O\u2019reilly","year":"2013","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.autrev.2020.102730_bb0415","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ajpath.2011.09.013","article-title":"Blockade of Interleukin-6 receptor alleviates disease in mouse model of scleroderma","volume":"180","author":"Kitaba","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2020.102730_bb0420","doi-asserted-by":"crossref","first-page":"87.2","DOI":"10.1136\/annrheumdis-2015-eular.2281","article-title":"OP0054 safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis: week 48 data from the Fasscinate trial","volume":"74","author":"Khanna","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102730_bb0425","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ejcb.2015.08.001","article-title":"Fibroblast heterogeneity and its implications for engineering organotypic skin models in vitro","volume":"94","author":"Sriram","year":"2015","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.autrev.2020.102730_bb0430","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.4049\/jimmunol.180.3.1598","article-title":"Human mesenchymal stem cells license adult CD34+Hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the notch pathway","volume":"180","author":"Li","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2020.102730_bb0435","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.stem.2012.03.007","article-title":"Mesenchymal-stem-cell-induced Immunoregulation involves FAS-ligand-\/FAS-mediated T cell apoptosis","volume":"10","author":"Akiyama","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.autrev.2020.102730_bb0440","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.apjtm.2016.10.005","article-title":"Adipose tissue-derived stem cells ameliorates dermal fibrosis in a mouse model of scleroderma","volume":"10","author":"Chen","year":"2017","journal-title":"Asian Pac J Trop Med"},{"key":"10.1016\/j.autrev.2020.102730_bb0445","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/01.CIR.0000114522.38265.61","article-title":"Plasticity of human adipose lineage cells toward endothelial cells","volume":"109","author":"Planat-Benard","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2020.102730_bb0450","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10067-010-1610-4","article-title":"Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis","volume":"30","author":"Hasegawa","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2020.102730_bb0455","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.0022-202X.2005.23767.x","article-title":"Abnormal natural killer cell function in systemic sclerosis: altered cytokine production and defective killing activity","volume":"125","author":"Horikawa","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2020.102730_bb0460","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/art.39477","article-title":"Antifibrotic, antioxidant, and immunomodulatory effects of mesenchymal stem cells in HOCl-induced systemic sclerosis","volume":"68","author":"Maria","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2020.102730_bb0465","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0092-8674(01)00328-2","article-title":"Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell","volume":"105","author":"Krause","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2020.102730_bb0470","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3892\/ijmm.2012.1015","article-title":"Therapeutic potential of bone marrow-derived mesenchymal stem cells producing pigment epithelium-derived factor in lung carcinoma","volume":"30","author":"Chen","year":"2012","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.autrev.2020.102730_bb0475","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.imlet.2016.02.016","article-title":"In vivo immunomodulatory effects of adipose-derived mesenchymal stem cells conditioned medium in experimental autoimmune encephalomyelitis","volume":"172","author":"Yousefi","year":"2016","journal-title":"Immunol Lett"},{"key":"10.1016\/j.autrev.2020.102730_bb0480","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/art.24405","article-title":"Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells","volume":"60","author":"Gonz\u00e1lez","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102730_bb0485","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.3727\/096368914X685645","article-title":"Adipose tissue-derived mesenchymal stem cells induce expansion of Interleukin-10-producing regulatory B cells and ameliorate autoimmunity in a murine model of systemic lupus erythematosus","volume":"24","author":"Park","year":"2015","journal-title":"Cell Transplant"},{"issue":"241\u2013245","key":"10.1016\/j.autrev.2020.102730_bb0490","article-title":"Internal involvement in localized scleroderma","volume":"73","author":"Dehen","year":"1994","journal-title":"Med (Baltim)"},{"key":"10.1016\/j.autrev.2020.102730_bb0495","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/rheumatology\/ken405","article-title":"Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis","volume":"48","author":"Badea","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2020.102730_bb0500","doi-asserted-by":"crossref","first-page":"1284687","DOI":"10.1155\/2018\/6984282","article-title":"From localized scleroderma to systemic sclerosis: coexistence or possible evolution (Dermatology Research and Practice)","volume":"2018","author":"Giuggioli","year":"2018","journal-title":"Dermatol Res Pract"},{"key":"10.1016\/j.autrev.2020.102730_bb0505","series-title":"Localized scleroderma progressing to systemic disease","first-page":"410","volume":"36","author":"Birdi","year":"1993"},{"key":"10.1016\/j.autrev.2020.102730_bb0510","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/1284687","article-title":"From localized scleroderma to systemic sclerosis: coexistence or possible evolution","volume":"2018","author":"Dilia","year":"2018","journal-title":"Dermatol Res Pract"},{"key":"10.1016\/j.autrev.2020.102730_bb0515","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1590\/abd1806-4841.20152890","article-title":"Localized scleroderma: clinical spectrum and therapeutic update","volume":"90","author":"Careta","year":"2015","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.autrev.2020.102730_bb0520","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00403-014-1466-6","article-title":"Topical vitamin D analogue calcipotriol reduces skin fibrosis in experimental scleroderma","volume":"306","author":"Usategui","year":"2014","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.autrev.2020.102730_bb0525","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jaad.2010.09.006","article-title":"A systematic review of morphea treatments and therapeutic algorithm","volume":"65","author":"Zwischenberger","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2020.102730_bb0530","first-page":"33","article-title":"An update on the treatment of the cutaneous manifestations of systemic sclerosis: the dermatologist\u2019s point of view","volume":"5","author":"Vitiello","year":"2012","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.autrev.2020.102730_bb0535","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/rheumatology\/41.3.324","article-title":"Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud\u2019s phenomeon and systematic sclerosis","volume":"41","author":"Anderson","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2020.102730_bb0540","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s40674-014-0006-z","article-title":"Management of Raynaud\u2019s phenomenon and digital ulcers","volume":"1","author":"Wigley","year":"2015","journal-title":"Curr Treat Options Rheumatol"},{"year":"1999","series-title":"Topical tocoretinate improved hypertrophic scar, skin sclerosis in systemic sclerosis and Morphea","author":"Mizutani","key":"10.1016\/j.autrev.2020.102730_bb0545"},{"key":"10.1016\/j.autrev.2020.102730_bb0550","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2133.2004.06318.x","article-title":"Localized scleroderma: response to occlusive treatment with tacrolimus ointment [6]","volume":"152","author":"Mancuso","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2020.102730_bb0555","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1346-8138.2008.00552.x","article-title":"Topical tacrolimus 0.1% ointment in the treatment of localized scleroderma. An open label clinical and histological study","volume":"35","author":"Stefanaki","year":"2008","journal-title":"J Dermatol"},{"key":"10.1016\/j.autrev.2020.102730_bb0560","doi-asserted-by":"crossref","first-page":"S724","DOI":"10.1136\/annrheumdis-2020-217407","article-title":"Systemic sclerosis and the COVID-19 pandemic: world Scleroderma Foundation preliminary advice for patient management","volume":"79","author":"Matucci-Cerinic","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102730_bb0565","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1007\/s10067-020-05193-2","article-title":"The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress","volume":"39","author":"Orlandi","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2020.102730_bb0570","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1378\/chest.07-2444","article-title":"High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease","volume":"134","author":"Goldin","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2020.102730_bb0575","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.autrev.2020.102730_bb0580","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102730_bb0585","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220303116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220303116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:19:25Z","timestamp":1761599965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997220303116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":117,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1568997220303116"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102730","relation":{},"ISSN":["1568-9972"],"issn-type":[{"type":"print","value":"1568-9972"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted delivery in scleroderma fibrosis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102730","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102730"}}